Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23 , Pages S31-S38 , December 2009

5 Long-term acromegaly and associated cardiovascular complications: a case-based review

  • Annamaria Colao

      Affiliations

    • Corresponding Author InformationCorrespondence: Annamaria Colao, MD, PhD. Università degli Studi di Napoli Federico II, Department of Molecular and Clinical Endocrinology and Oncology, Via S. Pansini 5, 80131 Napoli, Italy. Tel.: +39 081 7462132; fax: +39 081 5465443

References 

  1. Melmed S . Medical progress: Acromegaly . The New England Journal of Medicine . 2006;355:2558–2573
  2. Melmed S , Colao A , Barkan A , et al.   Guidelines for acromegaly management: an update . Journal of Clinical Endocrinology and Metabolism . 2009;94:1509–1517
  3. Melmed S . Acromegaly and cancer: not a problem? . Journal of Clinical Endocrinology and Metabolism . 2001;86:2929–2934
  4. Colao A . The GH-IGF-I axis and the cardiovascular system: clinical implications . Clinical Endocrinology (Oxford) . 2008;69:347–358
  5. Delafontaine P . Insulin-like growth factor I and its binding proteins in the cardiovascular system . Cardiovascular Research . 1995;30:825–834
  6. Chen DB , Wang L , Wang PH . Insulin-like growth factor I retards apoptotic signaling induced by ethanol in cardiomyocytes . Life Sciences . 2000;67:1683–1693
  7. Cittadini A , Ishiguro Y , Strömer H , et al.   Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles . Circulation Research . 1998;83:50–59
  8. Freestone NS , Ribaric S , Mason WT . The effect of insulin-like growth factor-1 on adult rat cardiac contractility . Molecular and Cellular Biochemistry . 1996;163–164:223–239
  9. Ito H , Hiroe M , Hirata Y , et al.   Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes . Circulation . 1993;87:1715–1721
  10. Colao A , Ferone D , Marzullo P , et al.   Systemic complications of acromegaly: epidemiology, pathogenesis, and management . Endocrine Reviews . 2004;25:102–152
  11. Bayes-Genis A , Conover CA , Schwartz RS . The insulin-like growth factor axis: A review of atherosclerosis and restenosis . Circulation Research . 2000;86:125–130
  12. Juul A , Scheike T , Davidsen M , et al.   Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study . Circulation . 2002;106:939–944
  13. Vasan RS , Sullivan LM , D'Agostino RB , et al.   Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study . Annals of Internal Medicine . 2003;139:642–648
  14. Laughlin GA , Barrett-Connor E , Criqui MH , et al.   The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study . Journal of Clinical Endocrinology and Metabolism . 2004;89:114–120
  15. Johnsen SP , Hundborg HH , Sørensen HT , et al.   Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke . Journal of Clinical Endocrinology and Metabolism . 2005;90:5937–5941
  16. Denti L , Annoni V , Cattadori E , et al.   Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly . American Journal of Medicine . 2004;117:312–317
  17. Bondanelli M , Ambrosio MR , Onofri A , et al.   Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome . Journal of Clinical Endocrinology and Metabolism . 2006;91:3928–3934
  18. van den Beld AW , Blum WF , Pols HA , et al.   Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men . European Journal of Endocrinology . 2003;148:627–634
  19. Clayton RN . Cardiovascular function in acromegaly . Endocrine Reviews . 2003;24:272–277
  20. Clayton RN . New developments in the management of acromegaly. Should we achieve absolute biochemical cure . Journal of Endocrinology . 1997;155(Suppl. 1):S23–S29 discussion S31–S32.
  21. Bates AS , Van't Hoff W , Jones JM , Clayton RN . An audit of outcome of treatment in acromegaly . QJM . 1993;86:293–299
  22. Orme SM , McNally RJ , Cartwright RA , Belchetz PE . Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group . Journal of Clinical Endocrinology and Metabolism . 1998;83:2730–2734
  23. Rajasoorya C , Holdaway IM , Wrightson P , et al.   Determinants of clinical outcome and survival in acromegaly . Clinical Endocrinology (Oxford) . 1994;41:95–102
  24. Colao A , Ferone D , Marzullo P , Lombardi G . Systemic complications of acromegaly: epidemiology, pathogenesis, and management . Endocrine Reviews . 2004;25:102–152
  25. Wright AD , Hill DM , Lowy C , et al.   Mortality in acromegaly . QJM . 1970;39:1–16
  26. Etxabe J , Gaztambide S , Latorre P , et al.   Acromegaly: an epidemiological study . Journal of Endocrinological Investigation . 1993;16:181–187
  27. Abosch A , Tyrrell JB , Lamborn KR , et al.   Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results . Journal of Clinical Endocrinology and Metabolism . 1998;83:3411–3418
  28. Swearingen B , Barker FG , Katznelson L , et al.   Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly . Journal of Clinical Endocrinology and Metabolism . 1998;83:3419–3426
  29. Melmed S . Acromegaly and cancer: not a problem? . Journal of Clinical Endocrinology and Metabolism . 2001;86:2929–2934
  30. Vitale G , Pivonello R , Lombardi G , et al.   Cardiovascular complications in acromegaly . Minerva Endocrinologica . 2004;29:77–88
  31. Lombardi G , Galdiero M , Auriemma RS , et al.   Acromegaly and the cardiovascular system . Neuroendocrinology . 2006;83:211–217
  32. Colao A , Cuocolo A , Marzullo P , et al.   Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance . Journal of Clinical Endocrinology and Metabolism . 2001;86:1551–1557
  33. Colao A , Marzullo P , Cuocolo A , et al.   Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide . Clinical Endocrinology (Oxford) . 2003;58:169–176
  34. Colao A , Cappabianca P , Caron P , et al.   Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study . Clinical Endocrinology (Oxford) . 2009;70:757–768
  35. Colao A , Ferone D , Marzullo P , et al.   Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly . Journal of Clinical Endocrinology and Metabolism . 2001;86:2779–2786
  36. Giustina A , Bonadonna S , Bugari G , et al.   High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial . European Journal of Endocrinology . 2009; [Epub ahead of print].
  37. Colao A , Pivonello R , Auriemma RS , et al.   Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly . European Journal of Endocrinology . 2007;157:579–587
  38. Colao A , Pivonello R , Auriemma RS , et al.   Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months . Journal of Clinical Endocrinology and Metabolism . 2008;93:3436–3442

PII: S1521-690X(09)70006-5

doi: 10.1016/S1521-690X(09)70006-5

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23 , Pages S31-S38 , December 2009

Article Tools

* Image Usage & Resolution